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Summary
Background: Hypothalamic—pituitary—adrenal (HPA)-axis hyperactivity has been observed in
(recurrent) major depressive disorder (MDD), although inconsistently and mainly cross-sectional.
Longitudinal studies clarifying state-trait issues are lacking. We aimed to determine whether HPA-
axis (hyper)activity in recurrent MDD is: (I) reflecting a persistent trait; (II) influenced by
depressive state; (III) associated with stress or previous episodes; (IV) associated with recurrence;
and (V) influenced by cognitive therapy.
Methods: We included 187 remitted highly recurrent MDD-patients (mean number of previous
episodes: 6.3), participating in a randomized-controlled-trial investigating the preventive effect of
additional cognitive therapy on recurrence. In an add-on two-staged patient-control and prospec-
tive-cohort design, we first cross-sectionally compared patients’ salivary morning and evening
cortisol concentrations with 72 age- and sex-matched controls, and subsequently longitudinally
followed-up the patients with repeated measures after three months and two years.
Results: Patients had higher cortisol concentrations than controls ( p < .001), which did not
change by MDD-episodes during follow-up. HPA-axis activity had no relation with daily hassles
or childhood life events. Cortisol concentrations were lower in patients with more previous
episodes ( p = .047), but not associated with recurrence(s) during follow-up. Finally, randomly
assigned cognitive therapy at study-entry enhanced cortisol declines over the day throughout the
two-year follow-up ( p = .052).
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Conclusions: Our results indicate that remitted recurrent MDD-patients have a persistent trait of
increased cortisol concentrations, irrespective of stress. In combination with our finding that patients’
cortisol concentrations do not change during new MDD-episodes (and thus not represent epiphenom-
enal or state-effects), our results support that hypercortisolemia fulfills the state-independence
criterion for an endophenotype for recurrent depression.
# 2011 Elsevier Ltd. 
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Hypothalamic—pituitary—adrenal (HPA)-axis research in
major depressive disorder (MDD) has been predominantly
cross-sectional in nature, comparing patients in a depressed
state with healthy controls (Gold et al., 1986). Observations
of hypersecretion of corticotrophin releasing hormone
(Holsboer, 2000) and cortisol (Vreeburg et al., 2009a; Knorr
et al., 2010), reduced feedback from glucocorticoids
(Pariante and Miller, 2001), and enlarged endocrine glands
(Rubin et al., 1995), resulted in a general consensus of an HPA-
axis overdrive in patients with more severe forms of MDD
(Stetler and Miller, 2011). However there were also conflicting
data; (I) some studies observed no elevated or even lowered
cortisol concentrations in MDD-patients compared with con-
trols (Strickland et al., 2002; Ahrens et al., 2008; Carpenter
et al., 2009); (II) glucocorticoid treatment and diseases with
higher (e.g. Cushing’s), but also lower cortisol concentrations
(e.g. Addison’s; posttraumatic stress disorder) are both asso-
ciated with MDD (Oquendo et al., 2003; Starckmann, 2003;
Wolkowitz et al., 2009); and (III) treatments with glucocorti-
coid receptor agonists as well as antagonists have both been
proposed anti-depressogenic (Pariante, 2009).
In addition, it has been increasingly recognized that MDD is
a chronic recurrent disorder. Indicatively, at least 80% of
clinically recovered MDD-patients will experience a recur-
rence during 25-years follow-up (Bhagwagar and Cowen,
2008). With, on average, five subsequent major depressive
episodes (MDEs), the recurrent nature of MDD is a severe
burden to patients, families and societies (Greden, 2001;
Bockting et al., 2006; Bhagwagar and Cowen, 2008). The
predominant cross-sectional studies could not address the
association of HPA-axis disturbances with this recurrent
course of MDD. More recently, longitudinal studies investi-
gated HPA-axis activity preceding, and subsequent to, the
depressed state. For example, HPA-axis hyperactivity was
also observed in remitted MDD-patients (Bhagwagar et al.,
2003; Vreeburg et al., 2009a), although others found no
differences or even hypoactivity (Van Den Eede et al.,
2006; Ahrens et al., 2008). In addition, during transition from
an acute depressive state to remission, sustained HPA-axis
hyperactivity predicted recurrence during follow-up (Zobel
et al., 2001; Appelhof et al., 2006). Likewise, higher cortisol
concentrations in adolescents prospectively determined MDD
onset during follow-up (Goodyer et al., 2000).
Taken together these findings raise the question whether
abnormal HPA-axis activity in MDD-patients reflects a state
only during MDEs, and/or represents a persistent trait. This
question is not merely of academic importance. For example,
if HPA-axis abnormalities show to be state-dependent, these
abnormalities could mediate some of the MDE-symptoms and
scarring effects. Proven true, treatment during a MDE direc-
ted at normalizing HPA-axis activity could reduce thesesymptoms and prevent scarring. On the other hand, if HPA-
axis abnormalities show to be a trait, they could be involved
in the pathogenesis of a new or recurrent MDE. If so, pre-
ventive treatment directed at normalizing HPA-axis activity
could be indicated (Pariante, 2009). For example, cognitive
therapy could be a promising candidate as it was shown to
protect against recurrences (Bockting et al., 2005) and to
normalize HPA-axis activity (Hsiao et al., 2011).
Besides these clinical aspects of the state-trait discussion,
it also poses pathogenetic issues. If HPA-axis abnormalities
show to be state-dependent, they might be the consequence
of epiphenomenal effects of depressive symptoms or accom-
panying daily hassles. On the contrary, if HPA-axis abnorm-
alities show to be a trait, they might be the consequence of
traumatizing childhood life-events (CLEs) (Heim et al.,
2001), scarring-effects of previous MDEs (Kendler et al.,
2000) and/or perinatal programming (Matthews, 2002), but
could also be genetically regulated (endophenotype) (Hasler
et al., 2004). This latter hypothesis is strengthened by pre-
vious research showing evidence that fulfilled the following
endophenotype criteria: familial association (Mannie et al.,
2007), cosegregation (Holsboer et al., 1995), and heritability
(Bartels et al., 2003). However, the endophenotype state-
independence criterion, i.e. ‘‘manifests in an individual
whether or not illness is active’’ (Gottesman and Gould,
2003), has, to our knowledge, not yet been addressed for
HPA-axis activity in MDD.
To further clarify these state-trait issues, we performed a
longitudinal study to assess HPA-axis activity over time in
highly recurrent MDD-patients. At study entry all patients
were in remission, and compared with a matched control
group. Subsequently, the patients were followed-up prospec-
tively at three months and two years, while MDD-recurrence
and HPA-axis activity were monitored.
We hypothesized that in patients with recurrent MDD HPA-
axis hyperactivity: (I) reflects a trait, i.e. remitted patients
exhibit higher cortisol concentrations compared with con-
trols; (II) is additionally influenced by depressive state (i.e.
more outspoken HPA-axis abnormalities during a recurrent
MDE at follow-up); (III) is associated with (a) current daily
hassles, (b) CLEs, and (c) number of previous MDEs. Further-
more, we hypothesized that: (IV) cortisol concentrations are
higher in patients who experience recurrence(s), compared
with patients who remain in remission during the entire
follow-up period; and finally that (V) preventive cognitive
therapy normalizes heightened HPA-axis activity.
2. Methods and materials
2.1. Design
The patient sample used in this study was recruited at
psychiatric centers and through media announcements to
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rence-preventing effects of cognitive therapy (CT) in recur-
rent MDD (Bockting et al., 2005). We used an add-on two-
staged case—control and prospective-cohort design. First, we
cross-sectionally compared patients with controls at study-
entry (T0) in the case—control stage. Subsequently we long-
itudinally followed-up the patients with repeated measures
at three months (T1; after the CT-intervention period) and
two years (T2) in the prospective-cohort stage, to assess
short- and long-term (I) stability of patients’ characteristics
and (II) effects of CT.
We allocated eligible patients to treatment as usual or to
an additional preventive CT-module (Bockting et al., 2005).
This module consisted of eight weekly group sessions, focus-
ing on dysfunctional attitude identification and change.
Treatment as usual involved ‘naturalistic’ care, ranging from
continuous antidepressant use to no treatment at all. The
study was approved by the ethics committee of the Academic
Medical Center of the University of Amsterdam. All subjects
provided written informed consent.
2.2. Study sample
2.2.1. Patients
We included remitted MDD-patients (18—65 years), who had
experienced 2 MDEs in the last five years, according to the
DSM-IV and assessed by trained evaluators using the Struc-
tured Clinical Interview for DSM-IV disorders (SCID) (First
et al., 1996). Patients had to have reached remission status
>10 weeks and <2 years ago. We defined remission according
to DSM-IV criteria and a score 9 on the 17-item Hamilton
Depression Rating Scale (HDRS17) (Hamilton, 1960). We
excluded subjects with: (a history of) bipolar spectrum dis-
order; (a history of) any psychotic disorder; organic brain
damage; alcohol and/or drug abuse and/or dependency; or
predominant anxiety disorder, all assessed using the SCID.
Furthermore, current steroid use was also an exclusion cri-
terion.
2.2.2. Controls
We recruited age- and sex-matched controls by advertise-
ments in a diversity of newspapers and magazines. Controls
had to have no current or past (personal and/or family)
history of psychiatric axis-I disorders according to the DSM-
IV (assessed with the SCID). Furthermore, current steroid use
was an exclusion criterion for the controls as well.
2.3. Study measurements
2.3.1. Depression characteristics and covariates
For the case—control stage of our study, at T0, we deter-
mined educational level (low, middle, and high), anthropo-
metric measures (body mass index, waist and hip
circumference), smoking behavior and medication use
(including contraceptives) for both patients and controls.
During the prospective-cohort stage involving the
patients, we assessed the number of previous MDEs at T0.
As described previously (Bockting et al., 2005), the range of
previous MDEs was 2—70 (median = 4, interquartile
range = 3), and not normally distributed, which could not
be resolved by transformation. To test the effects of previousMDEs on HPA-axis activity, we therefore dichotomized the
variable previous MDEs. We chose a cut-off point that created
the most equally numbered groups of patients, to maximize
conceivable power and/or contrast. The optimal cut-off
point was the median (4), with 59.4% of the patients having
<5 pervious MDEs and 40.6% having 5 MDEs. In addition, we
assessed CLEs before the age of 16 with the 15-item Negative
Life Events Questionnaire (which we dichotomized; experi-
enced CLEs yes/no) (Kraaij and de Wilde, 2001). Events may
involve the participant or significant others. This question-
naire proved to have a good predictive validity, as the number
of negative life events predicted MDD-symptom severity
(Kraaij et al., 2003). We measured daily hassles at T0, with
the 114-item Everyday Problem Checklist, providing a con-
tinuous score (Vingerhoets and van Tilburg, 1994). Finally we
assessed MDD-symptoms, in addition to the SCID, with the
Beck Depression Inventory (BDI), at T0 (Beck et al., 1979).
During follow-up, we repeated the assessments of daily
hassles and MDD-symptoms at T1 and T2, with the Everyday
Problem Checklist, BDI and SCID. With these follow-up assess-
ments of the SCID we diagnosed relapses (<6 months after a
previous MDE) or recurrences during follow-up, both further
addressed as ‘recurrence’ for clarity reasons. Furthermore,
during the whole follow-up, from T0 to T2, we monitored
antidepressant medication by using the Trimbos/IMTA Self
Report Questionnaire for Costs Associated With Psychiatric
Illness, every three months (Hakkaart-van Roijen et al.,
2002). To make data manageable for analyses, we operatio-
nalized antidepressant use as continuous antidepressant use
during follow-up (yes/no). The non-continuous group both
included patients who took antidepressants intermittently
and patients that did not take antidepressants at all (Bockt-
ing et al., 2008).
2.3.2. Hormone measures
For the case—control stage of the study, patients and controls
collected saliva with neutral cotton salivettes (Sarstedt AG
and Co, Nu¨mbrecht, Germany) at home at three sampling
moments on two consecutive days (day one: 0800 h and
2200 h; day two: 0800 h). For the prospective-cohort stage,
we repeated the T0 measures with follow-up measures at T1
and T2 in patients only. Saliva reliably reflects blood cortisol
concentrations, in a relatively stress-free and minimally
intrusive way (Kirschbaum and Hellhammer, 1994). We
instructed subjects to rinse their mouth with water and
not to brush their teeth before sampling. Subjects collected
morning samples after an overnight fast, and kept the sam-
ples in the refrigerator until they sent them back by mail on
day two. We stored samples at 20 8C until analysis by
radioimmunoassay (IBL Hamburg; designed for saliva sam-
ples). Intra- and interassay variations were 5.1% and 6.5%,
respectively.
2.4. Statistical analysis
2.4.1. Data cleaning, imputation
We assigned cortisol concentrations that exceeded four stan-
dard deviations from the mean as missing, because this
suggests blood contamination. To reduce bias potentially
introduced by missing values, we used a multiple imputation
technique using the package Amelia II (Honaker et al., 2010).
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handle missing values, and results in correctly estimated stan-
dard errors and confidence intervals (Donders et al., 2006). We
used multiple imputation separately for the cross-sectional
comparison between patients and controls and for the long-
itudinal analysis that only applied to the patients. Imputation
resulted in five imputed datasets for the cross-sectional case—
control analyses (imputation one) and five imputed data sets
for the longitudinal analyses of the patient-cohort (imputation
two). After imputation for T0, T1 and T2, we calculated the
mean of the two morning cortisol concentrations (day one and
two), since variability between morning measures on the two
consecutive days was equal for patients and controls. All
cortisol values showed normal distributions after log transfor-
mations, which we used in all analyses.
2.4.2. Subject characteristics and propensity scores
We compared patients’ and controls’ baseline characteristics
using x2 and Student’s t-test statistics. In further analyses we
adjusted for confounders using propensity scores, representing
the predicted probability for a case to belong to a certain group
(e.g. patient or control), calculated in a binary logistic model
with the chosen confounders as predictors (Rosenbaum and
Rubin, 1983). This way, we could correct for multiple con-
founders in one score at the same time without substantial loss
of power. We calculated a propensity score for comparisons
between patients and controls that corrects for common con-
founders (Vreeburg et al., 2009b): sex, age, educational level,
contraceptive use, steroid use in the month before assessment
(Hakkaart-van Roijen et al., 2002), smoking, weight and waist
and hip circumference (PS1). We created PS2 to adjust the
effect estimates in the longitudinal analyses, which, in addi-
tion to the confounders in PS1, also corrects for the potential
confounders: follow-up alcohol and drug use (yes/no), benzo-
diazepine therapy (yes/no), receiving CT treatment (yes/no)
and continuous antidepressant use (yes/no).
2.4.3. Models to distinguish trait and state-effects
To assess whether HPA-axis disturbances are a trait in MDD, we
used linear mixed models (Gueorguieva and Krystal, 2004),
with cortisol as the dependent variable and sampling
moment (morning/evening), group (patient/control) and
the moment  group-interaction as independent variables.
We used linear mixed models to incorporate correlations
between repeated measurements in the same subject,
thereby boosting power, and to achieve flexibility to model
time effects (Gueorguieva and Krystal, 2004). In case the
moment  group-interaction was non-significant, we removed
this term and used the remaining more parsimonious model.
We adjusted for confounders by adding PS1 to the final model.
To assess the effect of depressive state on cortisol, we
modeled depressive state as a time-dependent covariate. We
tested a linear mixed model using the longitudinal repeated
measures patients’ data with cortisol (T0, T1 and T2) as the
dependent variable, and follow-up time (T0, T1 and T2), sam-
pling moment (morning/evening), follow-up  moment-inter-
action, depressive state (indicated by the SCID at T0, T1 and T2)
and the state  moment-interaction as independent variables.
2.4.4. Additional analyses
To assess the association of CLEs (yes/no), number of pre-
vious MDEs (5 previous MDEs yes/no), and the occurrence ofrecurrence during follow-up (yes/no), with HPA-axis
activity, we one by one included these factors in subsequent
models with cortisol as dependent variable, and follow-up
time (T0, T1 and T2), sampling moment (morning/
evening), follow-up  moment-interaction, ‘‘factor’’ (yes/
no), ‘‘factor’’  moment-interaction, and ‘‘factor’’  fol-
low-up-interaction as independent variables. When a higher
order interaction did not contributed significantly to the
model, we removed this term and used the resulting more
parsimonious model. We determined the effect of daily
hassles on HPA-axis activity with a comparable model as
the one that was used for the state-effect, where the con-
tinuous Everyday Problem Checklist score replaced the state-
factor as a time-dependent variable. We adjusted for con-
founders by incorporating PS2 to the model.
To determine the effects of CT on HPA-axis activity, we
first tested whether the two randomized groups (CT yes/no)
were comparable on T0 (before CT). We then assessed the CT-
effect on cortisol at T1 and T2 (after CT).
We used PASW statistics 18.0 (SPSS, Inc., 2009, Chicago,
IL). For multivariate estimates we combined separate sig-
nificance tests for the five imputed datasets into one pooled
test with a SPSS macro from van Ginkel (2006). We considered
p < .05 statistically significant.
3. Results
3.1. Subject inclusion, hormone data and
characteristics (Table 1)
During the inclusion procedure, 1000 subjects (31% recruited
at psychiatric centers, and 69% through media announce-
ments) completed telephonic screening, and 321 were
invited for diagnostic interviews. Eventually, 187 patients
and 72 controls were eligible to participate. This recruit-
ment led to 1683 conceivable cortisol measures for patients
and 216 for controls. Of the 187 included patients, 15
dropped out of the study’s CT treatment immediately, but
we were able to collect HPA-axis data and so they were
included in all analyses. Drop-outs were younger than com-
pleters, but did not differ on other characteristics ( p > .05).
For the 172 remaining patients, 10.7%, 21.7% and 42.6%
measures were missing at T0, T1 and T2 respectively. For
the 216 conceivable values of the 72 controls, 10.6% of the
measures were missing. Of the 1361 complete measures,
seven values were assigned missing because of suggestive
blood contamination.
Patients and controls were successfully matched regard-
ing age and sex. The included patient group was character-
ized by high recurrence rates; the mean number of previous
MDEs was 6.3, and 54.5% had a recurrence during the two-
year follow-up.
3.2. HPA-axis disturbance as a trait (Fig. 1)
Remitted patients had significantly higher cortisol concen-
trations than controls (group-effect; p < .001; adjusted for
potential confounders [using PS1]). The course over the day
was not significantly different between patients and controls
and therefore omitted from the model (group  moment-
interaction; p = .376).
Figure 1 Morning and evening cortisol concentrations for re-
mitted recurrent MDD-patients compared to controls. All results
are adjusted for sex, age, educational level, contraceptive and
steroid use, smoking, weight and waist and hip circumference.
Error bars indicate SE. Mixed model analyses results: remitted
patients versus controls F1,656.13 = 14.77, p < .001.
Table 1 Subject characteristics.
Characteristic Patients (n = 187) Controls (n = 72) p Value
Female, % 68.1 72.7 .46
Age, mean (SD), year 44.2 (9.7) 44.9 (9.3) .61
Educational level a <.001
Low, % 33.2 4.6
Middle, % 32.6 19.7
High, % 34.2 72.3
Smoking, % 29.9 22.9 .28
Weight, mean (SD), kg 78.9 (16.3) 73.8 (13.4) .04
Waist circumference, mean (SD), cm 89.3 (13.9) 83.7 (12.3) .01
Hip circumference, mean (SD), cm 105.3 (11.1) 103.1 (7.8) .13
Oral contraceptive use, % 22.1 17.1 .40
Steroid useb, % .6 1.4 .57
Benzodiazepine use, % 8.0 NA
Continuous AD use during follow-up, % 27.3 NA
Antidepressant use at study entry, % 42.2 NA
TCA, % 3.9 NA
SSRI, % 29.2 NA
Other, % 9.1 NA
Received cognitive therapy, % 51.9 NA
HDRS17 score, mean (SD) 3.8 (2.9) NA
Number of previous episodes, mean (SD) 6.3 (8.1) NA
Five or more previous episodes, % 40.6 NA
Age of onset first episode, mean (SD), year 28.5 (12.5) NA
Relapse during the 2 year follow-up period, % 54.5 NA
Depressed at T1, % 15.0 NA
Depressed at T2, % 16.0 NA
Negative early life events, % 50.3 NA
Daily hassles score T0, mean (SD) 52.5 (38.9) NA
Daily hassles score T1, mean (SD) 41.3 (30.2) NA
Daily hassles score T2, mean (SD) 42.2 (35.1) NA
Abbreviations–—AD: antidepressant; HDRS: Hamilton depression rating scale; SSRI: selective serotonin reuptake inhibitor; T0, T1, T2: study-
entry 3 months and 2 years of follow-up respectively; TCA: tricyclic antidepressant.
a Educational level is defined as: low primary education or preparatory middle-level applied education; middle higher general continued
education or middle-level applied education; and high preparatory scientific education higher applied education or scientific education.
b Steroid use in the month before assessment.
896 A. Lok et al.3.3. HPA-axis disturbance as a state (Fig. 2)
The within-subject time-dependent variable modeling
depressive state (current MDE during follow-up measure-
ment) had no significant influence on cortisol concentrations
(state-effect; p = .419), after omission of the non-significant
effect on course over the day (state  moment-interaction;
p = .833).
In addition, the continuous BDI-score was used to assess
state-effects as well. This approach also did not reveal any
significant state-effects ( p = .467). Correction for possible
confounding by antidepressant use did not change these
findings.
3.4. Influence of daily hassles, CLEs and previous
episodes (Fig. 3)
The interaction of daily hassle score on a given time point
during follow-up (T0, T1 and T2) with moment, was not
significant and therefore omitted (hassles  moment-inter-
action; p = .249). This indicates there were no associations
Figure 3 Cortisol concentrations in relation to the experience
of childhood life events and the number of previous episodes
(<5/5) in recurrently depressed patients during a two-year
follow-up (T0, T1 and T2). All results are adjusted for sex, age,
educational level, contraceptive and steroid use, smoking,
weight and waist and hip circumference, alcohol and drug use
(yes/no), benzodiazepine therapy (yes/no), receiving CT treat-
ment (yes/no) and using continuous antidepressants (yes/no).
Mixed model analyses results for the effect of CLEs: CLEs (yes/
no) F1,12.14 = 1.435, p = .254. Mixed model analyses results for
previous episodes: 5 previous episodes (yes/no)
F1,46.15 = 4.152, p = .047.
Figure 2 Effect of a current depressive episode at sampling
moment after three months (T1) and two years of follow-up (T2),
on cortisol concentrations in recurrently depressed patients.
Error bars indicate SE. Mixed model analyses results: being
depressed according to the SCID at sampling moment (yes/no)
F1,65.54 = .66, p = .419. Measures at study entry (T0) were includ-
ed in the analyses, but because none of the subjects was
depressed at that moment (exclusion criterion) T0 is not includ-
ed in this figure.
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subsequent most parsimonious model there were no associa-
tions between overall cortisol concentrations and daily hassle
score (hassles-effect; p = .744).
For CLEs, interactions with follow-up and moment were
not significant, and therefore omitted from the model. In the
subsequent most parsimonious model, the main-effect of
CLEs also was non-significant ( p = .254).
Regarding the number of previous episodes, there were
no significant differences in cortisol-course over the
day (MDEs  moment-interaction; p = .818) or follow-up
(MDEs  follow-up-interaction; p = .510) between patients
with <5 previous MDEs compared to patients with 5 pre-
vious MDEs, so these interactions were omitted from the
model. In the most parsimonious model the main-effect of
previous MDEs was significant (MDEs; p = .047), with lower
cortisol concentrations in the patients with 5 previous
MDEs, compared to the patients with <5 MDEs.
3.5. Association with recurrence (Fig. 4)
There were no differences in cortisol-courses over the day or
follow-up between patients who experienced a recurrence
compared with those who remained in remission (recurren-
ce  moment-interaction; p = .707, recurrence  follow-up-
interaction; p = .957). In the final, most parsimonious, model
the main effect of recurrence was also non-significant (recur-
rence during follow-up-effect; p = .513).
3.6. Effect of cognitive therapy (Fig. 5)
At T0, before CT, cortisol-course over the day was compar-
able between patients that were randomly assigned to
receive CT and patients that were assigned to not receive
CT (CT  moment-interaction; p = .216), and thereforeomitted. The main effect of CT was also non-significant
(CT-group-effect p = .430), indicating comparable cortisol
concentrations in the two randomized groups before rando-
mization to CT.
During follow-up after CT (T1 and T2), when comparing
the patients who received CT in the first eight weeks of the
study with patients who did not, the 3-way-interaction
between follow-up time (T1, T2), sampling moment and
CT was nonsignificant (CT  follow-up  moment-interac-
tion; p = .960), so this term was omitted. Thereafter, the
interaction of CT with follow-up was also nonsignificant
(CT  follow-up-interaction; p = .514) and omitted. In the
subsequent model, the interaction of CT with sampling
moment reached borderline significance (CT  moment-
interaction; p = .052), indicating steeper cortisol declines
over the day in patients who received CT.
Figure 4 Cortisol concentrations in recurrently depressed
patients who remained in remission during a two-year follow-
up (T0, T1 and T2) compared to those who did experience at least
one recurrence. All results are adjusted for sex, age, educational
level, contraceptive and steroid use, smoking, weight and waist
and hip circumference, alcohol and drug use (yes/no), benzodi-
azepine therapy (yes/no), receiving CT treatment (yes/no) and
using continuous antidepressants (yes/no). Error bars indicate
SE. Mixed model analyses results: experiencing a recurrence
during follow-up (yes/no) F1,135.90 = .43, p = .513.
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To our knowledge, this is the first HPA-axis study in remitted
patients with recurrent MDD which applied a longitudinal
repeated-measures design. With this design, we showed that
high cortisol represents a trait in recurrent MDD, while there
is no apparent state-effect.
First, we found significantly higher cortisol concentrations
in patients compared to controls, suggestive of HPA-axis
hyperactivity as a trait in recurrent MDD. Second, our dataFigure 5 Effect of a randomized 8-week cognitive therapy (CT)
module at study entry (T0), on cortisol concentrations after
three months (T1) and two years (T2) of follow-up, in recurrently
depressed patients. Error bars indicate SE. Mixed model analyses
results for CT: main effect of CT (yes/no) F1,68.07 = 3.07, p = .085,
and CT  sampling moment (morning/evening) interaction
F1,18.85 = 4.30, p = .052.did not show state-effects on HPA-axis activity, because
cortisol did not change during MDEs during follow-up. Third,
HPA-axis hyperactivity was neither associated with (a) daily
hassles (epiphenomenal effects), (b) CLEs (early program-
ming), nor (c) number of previous MDEs (i.e. scarring, which
on the contrary, was associated with lower cortisol concen-
trations). Fourth, in patients, the hypercortisolemic trait
was, unexpectedly, not associated with recurrence during
entire follow-up. Finally, CT caused long-lasting steeper
cortisol declines over the day during the two-year follow-
up (borderline significant).
4.1. Trait of increased cortisol
The present study corroborates with previous studies which
reported higher cortisol concentrations in remitted MDD-
patients (Bhagwagar et al., 2003; Vreeburg et al., 2009a),
thereby not supportive of earlier reports of HPA-axis hypoac-
tivity (Ahrens et al., 2008). As distinct from previous cross-
sectional studies comparing HPA-axis activity in heteroge-
neous samples (recurrent and first episode MDD-patients com-
bined) (Bhagwagar et al., 2003; Van Den Eede et al., 2006;
Ahrens et al., 2008), our data longitudinally describe the
course of the cortisol-abnormalities specifically in highly
recurrent MDD-patients. Previous more heterogeneous sam-
ples might possibly have underestimated HPA-axis abnormal-
ities (Vreeburg et al., 2009a). Our finding of persistently
elevated cortisol concentrations suggests a permanent hyper-
cortisolemic trait in this subpopulation of recurrent MDD-
patients. This is further supported by studies reporting sus-
tained higher cortisol concentrations preceding a first MDE
(Modell et al., 1998; Goodyer et al., 2000; Mannie et al., 2007).
4.2. Absence of state-effects
The absence of state effects in our two-year follow-up
comparing different levels of depressive symptoms within
subjects, extends and strengthens previous cross-sectional
research which reported no differences in cortisol between
currently depressed patients and remitted MDD-patients
(Vreeburg et al., 2009a). The absence of state-effects may
appear in contrast with previous treatment-studies, which
found changes in HPA-axis activity after acute MDE treatment
with antidepressants (Schule et al., 2009). Although sugges-
tive of state-dependent changes, this influence of antide-
pressants could also be explained by an effect of
antidepressants per se rather than a depressive state-effect
(Manthey et al., 2011). This is suggested by a study reporting
declines in salivary cortisol concentrations during recovery
from the depressive state only in responders to amitriptyline,
and not in paroxetine responders (Deuschle et al., 2003). In
addition, because our study is the first report of longitudinal
HPA-axis activity in recurrent MDD, we hope our finding of
state-independency encourages further replication.
4.3. The absence of HPA-axis activating effects
of daily hassles, childhood life events and
previous episodes
Our data showed no association between the daily hassle
scores and cortisol concentrations, rejecting the idea that
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nomenal effect on the HPA-axis in recurrent MDD. Also, CLEs
did not explain the observed hypercortisolemic trait, in line
with previous literature (Heim et al., 2001). However, unex-
pectedly, having 5 previous MDEs was associated with lower
cortisol concentrations, compared to patients with <5 pre-
vious MDEs, in our sample of recurrent MDD-patients. A
possible explanation for this specific association could be
that HPA-axis activity could exhaust, or get suppressed, after
the experience of multiple MDEs. This could resemble parts
of the effects of chronic stress on HPA-axis activity, e.g. as an
adaptation to its associated increased allostatic load (Heim
et al., 2000; Fries et al., 2005). Therefore, it could be
hypothesized that the hypercortisolaemic trait observed in
our patients is attenuated by the experience of MDEs. This
could imply that the trait would have been more pronounced
in our patients if we would have measured them before they
experienced their MDEs.
4.4. Hypercortisolemia in recurrent MDD as an
endophenotype
The absence of HPA-axis activating effects of exogenous
factors in our sample, e.g. daily hassles, CLEs, and scarring
effects of previous MDEs, may indicate a more endogenously
regulated sustained HPA-axis hyperactivity. In addition, pre-
vious research found familial association (Mannie et al.,
2007), cosegregation (Holsboer et al., 1995), and heritability
(Bartels et al., 2003) of HPA-axis activity (Hasler et al., 2004),
all criteria of an endophenotype, thereby suggestive of HPA-
axis hyperactivity as an endophenotype. However, the state-
independence criterion for an endophenotype, has to our
knowledge not yet been addressed. With our observations of
a state-independent HPA-axis hyperactivity trait, all criteria
for hypercortisolemia as an endophenotype for recurrent
MDD could be considered to have been fulfilled. We hope
our observations will stimulate future research into the
evolutionary nature of hypercortisolemia in MDD (Nesse,
2000; Putman and Roelofs, 2011).
4.5. The association between HPA-axis activity
and recurrence
We observed no association between repeatedly measured
follow-up cortisol concentrations in our patients and the
occurrence of recurrence(s) during this follow-up. This is
consistent with studies that found no association between
cortisol concentrations measured once at the start of a
follow-up in long-term remitted patients and their prospec-
tive recurrence(s) (Bouhuys et al., 2006; Aubry et al., 2007).
In contrast, after acute treatment, persistently high cor-
tisol concentrations predicted recurrence during follow-up
(Zobel et al., 2001; Appelhof et al., 2006; Hatzinger et al.,
2009). This discrepancy could be explained by differences in
study populations in the above mentioned two study-types:
(I) patients who were in long-term remission (e.g. in our study
>10 weeks), versus (II) acute treatment remitters. It could be
hypothesized that in the latter population the patients who
were not stabilized well by antidepressants had higher cor-
tisol concentrations (e.g. by a placebo-response), and sub-
sequent higher relapse-rates, and that these patients wereresponsible for the association between cortisol and relapse.
This merits further exploration.
4.6. Effect of CT
In our intention to treat analysis, CT had a — borderline
significant — effect of steeper cortisol declines over the day
throughout the 2-year follow-up. Because baseline declines
in cortisol did not differ and CTwas provided at random, this
effect suggests a long-lasting causal influence of CT-treat-
ment on the hypercortisolemic trait. Interestingly, these
findings could represent a biological underpinning for the
recurrence preventing effect of the CT module (Bockting
et al., 2009). This finding corresponds with previous findings
of steeper cortisol declines over the day in patients receiving
psychotherapy plus antidepressants compared to patients
receiving antidepressant monotherapy (Yang et al., 2009;
Hsiao et al., 2011). As far as we know, our data for the first
time show the long-lastingness of this effect over a two-year
follow-up in highly recurrent remitted MDD patients.
Depending on the definition used, the effect of CT on the
HPA-axis might seem in contradiction with the proposed
state-independence of HPA-axis activity (Gottesman and
Gould, 2003; Hasler et al., 2004). In our view, if any treat-
ment is aimed directly at an endophenotype, such as the HPA-
axis, and would be effective in the treatment of MDD-symp-
toms through this endophenotypic effect, it could be
observed that after treatment, HPA-axis activity is dimin-
ished together with a remission of symptoms. However, in this
case, it would not be a state-effect of MDD-symptoms on the
HPA-axis, but an effect of CT directly at the HPA-axis, coin-
ciding with changes in MDD-symptoms, and thereby in accor-
dance with the state-independence criterion.
The mechanisms underlying the observed effect of CT on
the HPA-axis are not elucidated yet. It could be hypothesized
that the preventive CT changes coping strategies, e.g. stress
perception, management of stress and generation of subse-
quent stress (Bockting et al., 2006). These effects could
possibly mediate its recurrence-preventive effects.
5. Limitations and strengths
Our study has its limitations that need to be addressed. First,
because of the longitudinal design and outpatient setting,
full compliance to all study protocol measurements and
timing could not be attained, resulting in potential bias from
missing values. The concern of bias may be reduced by the
observation that missing rates did not differ between
patients and controls (10.7% vs. 10.6%, respectively). In
addition, we aimed to reduce possible bias from missing
values by using multiple imputation, also enabling an inten-
tion to treat analysis for the effects of CTon cortisol (Donders
et al., 2006). Second, we only measured one morning con-
centration instead of the whole cortisol awakening response,
and so based our cortisol course over the day estimation on
two measurements. In addition, we asked subjects to provide
two 0800 h saliva samples, without assessing their actual
awakening times. Therefore, we do not know whether the
measured morning value falls into the cortisol awakening
response or not. However, all effects were estimated on these
values measured systematically using identical methodology,
900 A. Lok et al.in patients and controls and for baseline and follow-up.
Conceivable consequences of these shortcomings are two-
fold: it could have caused differences that were actually not
present, if patients handled the protocol differently than
controls. On the other hand, differences could be diminished
due to increases in external variability. Third, we did not
include information on sleep quality in our analyses. Dis-
rupted sleep might have influenced morning cortisol con-
centrations, which could have resulted in an overestimation
of the difference between the patients and controls (Vree-
burg et al., 2009a). Fourth, we did not follow-up the con-
trols. Although this was not essential to answer our research
questions, it would be very interesting to investigate stabi-
lity and reactivity (e.g. in response to daily hassles) of the
HPA-axis in the healthy control subjects in future research.
Fifth, we were unable to correct for diet and detailed life-
style variables, e.g. sedentary life style, employment sta-
tus, sampling day (weekday vs. weekend), that possibly
could have confounded results. Nevertheless, we had the
opportunity to correct for smoking, alcohol/drugs use, edu-
cational level, weight, waist and hip circumference using
propensity scores. These variables are associated with diet-
ary and lifestyle characteristics (Galobardes et al., 2000)
and primary mediators of their effects on the HPA-axis, and
therefore, the confounding possibly introduced by the lack
of information on dietary and more detailed lifestyle factors
is expected to be minor. Sixth, we had inadequate power to
differentiate the diverse MDD-subtypes, e.g. melancholic,
atypical, which could be relevant in the activity of the HPA-
axis and therefore an interesting point for further research.
Finally, this study was not initially set up as a strictly
experimental endocrinological study. This might have
resulted in smaller effect sizes. However, the naturalistic
setting of our study enables follow-up of this clinical high-
risk population for two years.
Our study also had major strengths. First, our inclusion
procedure resulted in a well-defined patient sample, char-
acterized by high recurrence rates, reducing the change of
heterogeneity of patients and therefore inconsistent findings
(Wardenaar et al., 2011). This patient group is thought to (I)
represent a more biologically determined MDD-subtype, and
(II) contribute largely to the major burden of MDD (Greden,
2001). Second, our longitudinal design enabled us, to our
knowledge for the first time, to repeatedly sample cortisol
concentrations over a two-year follow-up. This opened the
possibility to determine the course of, and unravel state- and
trait-effects in, HPA-axis activity.
6. Conclusion
In this longitudinal study on HPA-axis activity, we demon-
strated evidence for a trait of hypercortisolemia in remitted
patients with recurrent depression. Additionally, we found no
state-effects on HPA-axis activity when patients became
depressed again. These findings support the state-indepen-
dence criterion for HPA-axis activity, and together with pre-
vious endophenotypical characteristics, the evidence for
hypercortisolemia as an endophenotype for recurrent MDD
is thereby further strengthened. Finally, our data indicated
that preventive CT may improve the decline of cortisol over
the day, which might be linked to its therapeutic effects.Role of funding source
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